Cancer patients in Europe can now receive a life-extending drug invented and developed by scientists at Newcastle University.
Women with recurrent ovarian cancer have been given access to the Rubraca®, following approval of the drug by the European Medicines Agency (EMA).
This allows the drug to be available on the European market, but it has to be approved by the National Institute for Health and Care Excellence and the Scottish Medicines Consortium, before allowing ovarian cancer patients in the UK with a BRCA gene mutation to access the new treatment.
Rubraca® has been approved for ovarian cancer patients with a faulty BRCA gene.
What is Rubraca?
It was first discovered approximately 20 years ago, it came out of research initiated at Newcastle University by Cancer Research UK-funded scientists.
Studies have shown that the oral medication has a high success rate as 54% of women on clinical trials had complete or partial shrinkage of their tumour for an average of 9.2 months.
Each year, around 7,000 women are diagnosed with ovarian cancer across the UK and one in 50 women will develop the disease at some point in their life.
Around 15% to 20% of women with ovarian cancer will have a BRCA gene mutation, putting them at increased risk of developing other cancers and a 50% risk of passing the faulty gene to their children.
A patient’s story
Susan Ross has been on Rubraca® under Dr Drew’s care at the Freeman Hospital’s Northern Centre for Cancer Care in Newcastle for more than two years.
The 60-year-old from Whitley Bay, was diagnosed with ovarian cancer with a BRCA gene mutation over 10 years ago and says she feels 'great' after being given the drug as part of a clinical trial.
Susan has been on Rubraca® since December 2015, when her ovarian cancer returned and was not operable.
Her tumour has shrunk completely and she continues to receive the treatment as part of a clinical trial.
Susan underwent four operations and three rounds of chemotherapy before being enrolled on the clinical trial.
She continues to be closely monitored with regular CT scans.